This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Brigham and Women's doctors research new treatments for severe asthma

May 11th, 2012

Chronic asthma sufferers may have new hope for relief due to two new research studies that are getting underway at Brigham and Women's Hospital (BWH). Researchers from BWH's Asthma Research Center are exploring whether two new therapies will relieve asthma symptoms.

In the first clinical trial, volunteers with mild to moderate asthma will be randomly selected to receive vitamin D, along with an asthma controller medication, while others will be selected at random to receive a placebo. Researchers believe that vitamin D might play an important role in reducing the inflammation that interferes with breathing.

In the second clinical trial, participants with hard-to-control asthma will be randomly selected to receive a medication called Imatinib or a placebo. Imatinib is approved by the Food and Drug Administration (FDA) to treat leukemia, but researchers hypothesize that it could also benefit asthma sufferers because it works by targeting specific cells that may also play a role in asthma and inflammation.

"The results of this research may present a great opportunity to bring relief to long-suffering asthma patients," said Elliot Israel, MD, director of the Asthma Research Center. "Additionally, as part of the studies, participants can learn key asthma management techniques."

More information:
Patients who are at least 18 years old and have asthma may be eligible to take part in these studies.

To learn more, email arc@partners.org or call (617) 732-8201.

Provided by Brigham and Women's Hospital

Citation: Brigham and Women's doctors research new treatments for severe asthma (2012, May 11) retrieved 21 June 2025 from https://sciencex.com/wire-news/98192836/brigham-and-womens-doctors-research-new-treatments-for-severe-as.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.